Sepsis Diagnostics Market Study including Growth Factors, Types and Application by regions from 2023 to 2030

 Sepsis Diagnostics Industry Overview

The global Sepsis Diagnostics Market size is expected to reach USD 1.4 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.6% over the forecast period. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period. Sepsis is a bloodstream disease that occurs as a result of a response to pathogenic microorganisms present in the blood. Patients suffering from this disease experience severe inflammation, which leads to prolonged hospitalization.

According to the WHO, around 30 million people are estimated to be affected by this disease every year. The NCBI stated that the largest number of this condition have been observed in the youngest and oldest age groups. Thus, there is a rising need for the early diagnosis of this disease. The WHO reported that every year, 1.2 million children and 3 million newborns are affected by this disease across the world. This has further boosted the demand for its diagnostic tools for quick results and improved patient outcomes. Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions for sepsis are expected to facilitate market growth over the forecast period.

In May 2018, T2 Biosystems, Inc., a U.S.-based emerging diagnostic solutions company, received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. The COVID-19 pandemic affected the growth of diagnostics products for sepsis in a moderately positive way. The worldwide spread of Coronavirus and the arising instances of sepsis among COVID-19 patients are probably going to expand the interest for fast detection, speeding up the use of instruments, reagents, and assay kits for recognition of sepsis. Pandemic-induced lockdown and other restrictions made individuals delay going through wellbeing checkups, influencing the number of tests performed and reagent deals.

The pandemic has featured the risk upon elders, who are more defenseless to complications, including intense respiratory distress condition, typically because of pneumonia, which builds the risk of creating sepsis. This has created a need for the early detection of sepsis among patients with COVID-19. Symptoms of sepsis, such as multiorgan injuries, develop in around 2.0 to 5.0% of COVID-19 cases 8 to 10 days post-hospitalization, based on the estimates of the Global Sepsis Alliance. To manage this situation, the Biomedical Advanced Research and Development Authority, in May 2020, extended its partnership with Beckman Coulter for the development of a digital algorithm to detect sepsis in patients with COVID-19.

Sepsis Diagnostics Market Segmentation

Grand View Research has segmented the global sepsis diagnostics market based on product, technology, pathogen, testing type, end-user, method and region:

Based on the Product Insights, the market is segmented into Instruments, Blood Culture Media and Assay Kits & Reagents.

• The blood culture media product segment dominated the global market in 2021 and accounted for the largest share of more than 45.5% of the total revenue. The segment is expected to maintain its lead over the forecast period.
• The instruments segments are also reported to show a constant growth rate over the forecast period owing to the rising awareness among the general population about healthcare and the increasing rate of surgical procedures.

Based on the Technology Insights, the market is segmented into Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry and Others.

• The microbiology technology segment dominated the global market and accounted for the largest share of more than 48.5% of the overall revenue. This can be attributed to the fact that microbiology technology allows accurate detection and identification of microorganisms for sepsis diagnosis through the application of culture media tests.
• The molecular diagnostics segment is anticipated to expand at the fastest CAGR over the forecast period. Increasing adoption of molecular diagnostic technology due to its several advantages, such as high sensitivity, accuracy, and less turnaround time, over other technologies is anticipated to drive the segment.

Based on the Pathogen Insights, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis and Others.

• The bacterial sepsis segment held the largest revenue share of 79.5% in 2021 and is anticipated to maintain its lead over the forecast period owing to the rise in cases of bacterial sepsis, the higher occurrence of hospital-transmitted infections, and the rising number of surgical procedures conducted.
• The fungal sepsis segment, although having less revenue share, is expected to maintain a significant CAGR over the forecast period. One of the major drivers of the pathogen segment is the increasing availability and the introduction of a new and wide range of sepsis diagnosis devices for pathogen detection.

Based on the Testing Type Insights, the market is segmented into Laboratory Testing and POC Testing.

• The laboratory testing type segment dominated the market in 2021 with a share of more than 85.00%. This is mainly due to the fact that lab testing has greater accuracy in comparison to POC testing while diagnosing sepsis.
• Clinical laboratory testingprovides an in-depth analysis of the pathogen and its drug resistance profile. In addition, routine testing of lactate levels, which are nonspecific, however, a useful marker of sepsis, is effectively performed in laboratory settings.

Based on the Method Insights, the market is segmented into Automated Diagnostics and Conventional Diagnostics.

Based on the End-User Insights, the market is segmented into Hospitals & Clinics, Pathology & Reference Laboratories and Research Institutes and Others.

Sepsis Diagnostics Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile

The key players operating in the market are adopting inorganic growth strategies, such as mergers and partnerships, for the development of novel diagnostic solutions.

Some prominent players in the global Sepsis Diagnostics market include

• bioMérieux SA
• Becton, Dickinson and Company
• Thermo Fisher Scientific, Inc.
• Hoffmann-La Roche AG
• Danaher CorporationLuminex Corporation
• Bruker Corporation
• Amara Health Analytics
• Wolters Kluwer N.V.
• Cerner Corporation
• Epic Systems Corp.
• Mckesson Corp.
• GE Healthcare
• Koninklijke Philips N.V.

Order a free sample PDF of the Sepsis Diagnostics Market Intelligence Study, published by Grand View Research.